Which drugs go off patent in 2033?
One blockbuster drug with $17.6B in 2025 worldwide sales loses US exclusivity in 2033: Skyrizi (AbbVie).
| Drug | Company | Area | 2025 sales | Date basis | US copies | Medicare price |
|---|---|---|---|---|---|---|
| Skyrizi | AbbVie | Immunology | $17.6B | Company guidance | No US filing found | – |
Every date here is fixed by a launch, settlement, court ruling or company guidance. Each drug's page has the sources.
| Company | Drugs | 2025 revenue from them | Share of company |
|---|---|---|---|
| AbbVie | Skyrizi | $17.6B | 29% |
For shared drugs, each company is credited with the revenue it reports, so nothing is counted twice. Share is of the company's total 2025 revenue.
Biosimilars usually erode a biologic's sales more gradually, because they are harder to make and switching takes longer.
US exclusivity can end earlier or later than these dates if a court ruling, settlement or new patent changes the picture. See what happened to sales after past patent cliffs →